



New Findings in Pharmacogenomics of Neuropsychiatric Disorders

Guest Editors:

Dr. Alireza Tafazoli

Laboratory of
Pharmacogenomics, Department
of Molecular
Neuropharmacology, Maj
Institute of Pharmacology Polish
Academy of Sciences, Kraków,
Poland

Dr. Mandana Hasanazad

Personalized Medicine Research
Center, Endocrinology and
Metabolism Clinical Sciences
Institute, Tehran University of
Medical Sciences, Tehran, Iran

Deadline for manuscript
submissions:

23 November 2024

Message from the Guest Editors

This Special Issue aims to bring together novel research findings that contribute to the field's understanding of the pharmacogenomics of neuropsychiatric disorders. By fostering discussions on genetic markers, treatment efficacy, and individualized approaches, this Special Issue aims to accelerate the translation of pharmacogenomic knowledge into clinical practice, ultimately improving the precision and effectiveness of drug treatments for individuals with neuropsychiatric disorders. This Special Issue also endeavors to spotlight the transformative role of cutting-edge genomic technologies in uncovering pharmacovariants relevant to neuropsychiatric disorders. These technologies, which include, but are not limited to, high-throughput sequencing, CRISPR-based technologies, and advanced bioinformatics tools, could pave the way to a more comprehensive exploration of the genetic landscape that influences drug responses.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e
Bioquímica (DQB) e Centro de
Química Estrutural (CQE),
Institute of Molecular Sciences,
Faculdade de Ciências,
Universidade de Lisboa, Lisboa,
Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com